$646 Million is the total value of Atlas Venture Life Science Advisors, LLC's 15 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | Disc Medicine, Inc. | $128,975,838 | -16.1% | 2,745,335 | -20.7% | 19.98% | +4.4% | |
| DAWN | Day One Biopharmaceuticals, Inc. | $93,354,994 | +2.8% | 7,608,394 | 0.0% | 14.46% | +27.9% | |
| DYN | Dyne Therapeutics, Inc. | $88,573,623 | -20.4% | 9,885,449 | 0.0% | 13.72% | -0.9% | |
| KYMR | Kymera Therapeutics, Inc. | $81,429,842 | -39.5% | 5,858,262 | 0.0% | 12.61% | -24.8% | |
| Third Harmonic Bio, Inc. | $69,701,219 | +32.8% | 10,907,859 | 0.0% | 10.80% | +65.4% | ||
| REPL | Replimune Group, Inc. | $35,901,913 | -26.3% | 2,098,300 | 0.0% | 5.56% | -8.3% | |
| Vigil Neuroscience, Inc. | $31,460,750 | -42.7% | 5,836,874 | 0.0% | 4.87% | -28.6% | ||
| GBIO | Generation Bio, Co. | $31,379,244 | -31.1% | 8,279,484 | 0.0% | 4.86% | -14.2% | |
| AVTE | Aerovate Therapeutics, Inc. | $27,672,609 | -20.9% | 2,039,249 | 0.0% | 4.29% | -1.5% | |
| IKNA | Ikena Oncology, Inc. | $21,728,711 | -34.0% | 5,018,178 | 0.0% | 3.36% | -17.9% | |
| AKRO | Sell | Akero Therapeutics, Inc. | $18,170,915 | -34.5% | 359,251 | -39.5% | 2.81% | -18.5% |
| AVRO | AvroBio, Inc. | $6,993,727 | +62.1% | 4,541,381 | 0.0% | 1.08% | +101.7% | |
| Xilio Therapeutics, Inc. | $5,822,216 | -19.5% | 2,759,344 | 0.0% | 0.90% | +0.2% | ||
| New | Dianthus Therapeutics, Inc. | $3,239,503 | – | 236,979 | +100.0% | 0.50% | – | |
| SPRO | Spero Therapeutics, Inc. | $1,226,260 | -16.6% | 1,013,438 | 0.0% | 0.19% | +3.8% | |
| MGTA | Exit | Magenta Therapeutics, Inc. | $0 | – | -3,791,698 | -100.0% | -0.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
| Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
| Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
| Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
| Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
| Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
| Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
| Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
| Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
| AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-09 |
| 13F-HR | 2022-08-03 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.